Avidia Research Institute and Boehringer Ingelheim Austria Enter Development and Manufacturing Agreement
"This collaboration brings together Avidia's expertise in the engineering of small therapeutic proteins with Boehringer Ingelheim Austria's track record in the development and manufacture of therapeutic proteins," said Dr. Van Vlasselaer, CEO at Avidia. "This will allow us to establish GMP processes for manufacturing Avidia's Maxybody proteins that will be very valuable as we start focusing on the clinical development of Maxybody protein-based therapeutic products. With Boehringer Ingelheim Austria as our partner, we are well positioned to successfully manufacture our products. This agreement greatly reduces the future risks for Avidia in the areas of process development and GMP manufacture."
"We have reviewed the merit of many peptide/antibody scaffold technologies and came to the conclusion that Avidia's technology compares favorably with other technologies we have evaluated. We are excited about the opportunity to work with Avidia and our decision underscores the value of its Maxybody protein technology," said Dr. Konopitzky, Head of Division Biopharmaceuticals / Operations at Boehringer Ingelheim Austria.
Other news from the department science
Most read news
More news from our other portals
See the theme worlds for related content
Topic world biopharmaceutical manufacturing
Biopharmaceutical production plays a crucial role in the development and manufacture of biologics, which are essential for the treatment of various serious diseases. Various key technologies and processes of the modern biopharmaceutical industry are used, such as cell cultures, fermentation processes and the purification of biological substances, which are necessary for the production of vaccines, monoclonal antibodies and other biological drugs.
Topic world biopharmaceutical manufacturing
Biopharmaceutical production plays a crucial role in the development and manufacture of biologics, which are essential for the treatment of various serious diseases. Various key technologies and processes of the modern biopharmaceutical industry are used, such as cell cultures, fermentation processes and the purification of biological substances, which are necessary for the production of vaccines, monoclonal antibodies and other biological drugs.